- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04585880
Remote Monitoring and Virtual Collaborative Care For Hypertension Control To Prevent Cognitive Decline (vCCC)
7 de julio de 2021 actualizado por: Jeff Burns, MD, University of Kansas Medical Center
Remote Monitoring and Virtual Collaborative Care For Hypertension Control To Prevent Cognitive Decline: Phase I
This purpose of this study is to examine an aggressive method of blood pressure control that involves home blood pressure monitoring and management of medications by a team of clinical pharmacists in coordination with a primary care physician.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
33
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66106
- University of Kansas Medical Center
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
65 años y mayores (Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Age 65 and older
- Active patient in participating primary care clinic
- Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity)
- Elevated blood pressure as defined by:
Systolic Blood Pressure >140 at current visit AND documented history of hypertension OR Systolic Blood Pressure > 140 at current visit and at another visit in last 18 months OR Systolic Blood Pressure >160 at current visit
- Sufficiently fluent in English to participate in study procedures
- Adequate vision and hearing to complete study procedures
Exclusion Criteria:
- Clinically significant illness that may affect safety or completion per their treating Primary Care Physician or study physician
- End stage renal disease on dialysis
- Chronic active disease with expected life expectancy < 2 years as determined by the study team
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Virtual Collaborative Care Clinic
The Virtual Collaborative Care Clinic arm participants use a home blood pressure monitor and routine blood pressure measurements will be uploaded to a dashboard monitored by clinical pharmacists.
Blood pressure will be managed aggressively by the clinical pharmacists in coordination with Primary Care Physicians.
|
The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care.
Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician.
As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
|
Sin intervención: Control Intervention
The control intervention will consist of providing the participant with educational material and a home blood pressure monitor.
The patients in the control group will not have support from Virtual Collaborative Care Clinic pharmacists.
Routine blood pressure measures using their device will not be collected via the dashboard and will not be available for pharmacist review.
Participants will continue to see their physicians for their usual care for blood pressure management.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Feasibility of system wide adoptability as assessed by survey responses
Periodo de tiempo: Baseline
|
Primary Care Physicians and vCCC Pharmacists will be asked for feedback on feasibility of implementation via a survey.
The vCCC pharmacists and PCPs will be surveyed to assess feasibility and changing views of feasibility.
Brief, validated scales will be delivered via email (REDCap surveys) to assess the construct of feasibility.
|
Baseline
|
Feasibility of system wide adoptability as assessed by survey responses
Periodo de tiempo: 3 Months Post Baseline
|
Primary Care Physicians and vCCC Pharmacists will be asked for feedback on feasibility of implementation via a survey.
The vCCC pharmacists and PCPs will be surveyed to assess feasibility and changing views of feasibility.
Brief, validated scales will be delivered via email (REDCap surveys) to assess the construct of feasibility.
|
3 Months Post Baseline
|
Feasibility of system wide adoptability as assessed by Physician Advisory Board meetings discussion
Periodo de tiempo: Through study completion, an average of 9 months
|
Members of the Physician Advisory Board will be asked for feedback on system wide adoptability during the monthly Physician Advisory Board meetings.
The meetings will be recorded and summarized.
|
Through study completion, an average of 9 months
|
Feasibility of system wide adoptability as assessed by vCCC Pharmacist Interviews
Periodo de tiempo: Up to 2 months Post Baseline
|
Virtual Collaborative Care Clinic Pharmacists will be asked for feedback on feasibility of system wide adoption.
We will conduct one-time semi-structured qualitative interviews with the Virtual Collaborative Care Clinic pharmacists.
The Virtual Collaborative Care Clinic pharmacist will be interviewed to assess implementation factors including the auto-referral process and open-ended questions on the process and suggestions for improvement.
|
Up to 2 months Post Baseline
|
Replicability to other health systems as assessed by survey responses
Periodo de tiempo: Baseline
|
Primary Care Physicians and vCCC Pharmacists will be asked for feedback on replicability to other health systems via a survey.
Brief, validated scales will be delivered via email (REDCap surveys) to assess the construct of replicability to other health systems.
|
Baseline
|
Replicability to other health systems as assessed by survey responses
Periodo de tiempo: 3 Months Post Baseline
|
Primary Care Physicians and vCCC Pharmacists will be asked for feedback on replicability to other health systems via a survey.
Brief, validated scales will be delivered via email (REDCap surveys) to assess the construct of replicability to other health systems.
|
3 Months Post Baseline
|
Replicability to other health systems as assessed by Physician Advisory Board meetings discussion
Periodo de tiempo: Through study completion, an average of 9 months
|
Members of the Physician Advisory Board will be asked for feedback on replicability to other health systems during the monthly Physician Advisory Board meetings.
The meetings will be recorded and summarized.
|
Through study completion, an average of 9 months
|
Replicability to other health systems as assessed by vCCC Pharmacist Interviews
Periodo de tiempo: Up to 2 months Post Baseline
|
vCCC Pharmacists will be asked for feedback on replicability to other health systems.
We will conduct one-time semi-structured qualitative interviews including open-ended questions.
|
Up to 2 months Post Baseline
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jeffrey Burns, MD, University of Kansas Medical Center
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
20 de octubre de 2020
Finalización primaria (Actual)
2 de julio de 2021
Finalización del estudio (Actual)
2 de julio de 2021
Fechas de registro del estudio
Enviado por primera vez
30 de septiembre de 2020
Primero enviado que cumplió con los criterios de control de calidad
9 de octubre de 2020
Publicado por primera vez (Actual)
14 de octubre de 2020
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
9 de julio de 2021
Última actualización enviada que cumplió con los criterios de control de calidad
7 de julio de 2021
Última verificación
1 de julio de 2021
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STUDY146086
- 1R61AG068483-01 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Virtual Collaborative Care Clinic
-
Abbott Medical DevicesActivo, no reclutandoEnfermedad de ParkinsonEstados Unidos, España, Alemania, Reino Unido